SCHEMBL7224534

SCHEMBL7224534

CC(=O)Nc1ccc(S(=O)(=O)Nc2cc(C)c(S(=O)(=O)C[N+](=O)[O-])c(C)c2)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
PKM P14618 3/20 0.47
POLB P06746 1/20 0.47
ALDH1A1 P00352 6/20 0.47
TDP1 Q9NUW8 2/20 0.43
MAPT P10636 2/20 0.43
IDH1 O75874 1/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40
PDK3 Q15120 1/20 0.40
PDK4 Q16654 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7229750 0.85 PKM (0.62) KMT2APKMPOLBALDH1A1TDP1
SCHEMBL7226067 0.83 PKM (0.61) KMT2APKMALDH1A1TDP1MAPT
SCHEMBL27457403 0.81 ALDH1A1 (0.58) KMT2APKMPOLBALDH1A1TDP1
SCHEMBL7222407 0.80 FFAR4 (0.49) KMT2APKMPOLBALDH1A1TDP1
SCHEMBL7223946 0.79 CYTH2 (0.46) KMT2APKMALDH1A1MAPTMEN1
SCHEMBL7225299 0.78 ALDH1A1 (0.43) KMT2APKMPOLBALDH1A1TDP1
SCHEMBL7225029 0.78 ALDH1A1 (0.50) KMT2ACA1CA2CA9PKM
SCHEMBL7221797 0.77 CYTH2 (0.43) KMT2ACA2CA9PKMALDH1A1
SCHEMBL7221678 0.77 CYTH2 (0.56) KMT2ACA1CA2CA9PKM
SCHEMBL7224301 0.76 KMT2A (0.50) KMT2APKMALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors COLLONGES FRANCOIS (FR) 2003-10-30 US disclosed
CN-1112356-C Nitromethylthiobenzene derivatives as inhibitors of aldose reductase MERCK PATENT GMBH (DE) 2003-06-25 CN disclosed
US-6509499-B1 Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment MERCK PATENTGESELLSCHAFT MIT (DE) 2003-01-21 US disclosed
EP-0946503-B1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GMBH (DE) 2002-03-27 EP disclosed
CN-1241997-A Nitromethylthiobenzene derivatives as inhibitors of aldose reductase MERCK PATENT GMBH (DE) 2000-01-19 CN disclosed
EP-0946503-A1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GmbH (DE) 1999-10-06 EP disclosed
WO-1998028265-A1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GMBH (DE) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors AKR1B1, ALDOA, AKR1C1 KMT2A 4070/4885CA1 3129/4885CA2 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.